Esperion Therapeutics (ESPR) Other Non Operating Income (2012 - 2026)

Esperion Therapeutics' Other Non Operating Income history runs 15 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• Quarterly Other Non Operating Income rose 10.35% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.3 million (down 91.75% YoY) and the FY2025 annual result came in at $3.5 million, down 56.49% from the prior year.
• Other Non Operating Income was $1.2 million for Q1 2026 at Esperion Therapeutics, down from $3.5 million in the prior quarter.
• Across five years, Other Non Operating Income topped out at $61.2 million in Q4 2024 and bottomed at -$4.2 million in Q4 2023.
• A 5-year average of $5.0 million and a median of $1.3 million in 2023 frame the typical range for Other Non Operating Income.
• Annual changes were most pronounced in 2022 — Other Non Operating Income surged 4969.23% — and 2023, when it tumbled 410.77%.
• Esperion Therapeutics' Other Non Operating Income stood at $1.4 million in 2022, then tumbled by 410.77% to -$4.2 million in 2023, then jumped by 1553.86% to $61.2 million in 2024, then sank by 94.3% to $3.5 million in 2025, then plunged by 66.1% to $1.2 million in 2026.
• Business Quant data shows ESPR's Other Non Operating Income at $1.2 million in Q1 2026, $3.5 million in Q4 2025, and $666000.0 in Q2 2025.